Tazemetostat Hydrobromide Tablet — FDA Drug Shortage

To Be Discontinued — Epizyme, Inc. (An Ipsen Company)

The FDA lists a drug shortage record for Tazemetostat Hydrobromide Tablet (tablet) from Epizyme, Inc. (An Ipsen Company) with status To Be Discontinued. The shortage was first posted on Mar 27, 2026.

Shortage details

Status
To Be Discontinued
Company
Epizyme, Inc. (An Ipsen Company)
Package NDC
72607-100-00
Dosage Form
Tablet
Presentation
Tazverik, Tablet, 200 mg (NDC 72607-100-00)
Initial Posting
Mar 27, 2026

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.